Bavarian Nordic has appointed Nicolai Buhl Andersen to head the newly established commercial function. He will join the company on 16 November 2007 as Executive Vice President, Commercial Affairs, and as part of Corporate Management he will be reporting to President & CEO, Anders Hedegaard.
Nicolai Buhl Andersen (born 1969) comes from Coloplast where he currently holds the position as Senior Vice President, Commercial Excellence. He has more than eight years of international experience in leading positions in the field of sales and marketing from Novo Nordisk. He holds a M.Sc. in Economics and Business Administration from Copenhagen Business School.
Anders Hedegaard, President & CEO of Bavarian Nordic, said: "With great international experience in sales and marketing, Nicolai Buhl Andersen has the ideal profile to head Bavarian Nordic's global commercial activities. The establishment of the commercial function as separate business area marks an important milestone for the company as it does not only strengthen our ongoing sales efforts for our third generation smallpox vaccine, IMVAMUNE® , but also ensures the integration of important market knowledge in the R&D activities so that these will focus even more on the commercial opportunities."
Asger Aamund
Chairman
Contacts:
Anders Hedegaard, President & CEO
Telephone: +45 33 26 83 83
Media: United Kingdom
Mary Clark, Capital MS&L
Telephone: +44 207 307 5330
Media: United States of America
Elizabeth Dempsey Becker, Bavarian Nordic Inc.
Telephone: +1 202 536-1576
